Kepos Capital’s ADMA Biologics ADMA Stock Holding History

Kepos Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-107,000	Closed	-$664K	–	336
2018 Q3	$664K	Hold	107,000	–	–	0.03%	270
2018 Q2	$483K	Buy	+107,000	New	+$533K	0.02%	283

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kepos Capital's ADMA Position: Q4 2018 in Review

Kepos Capital sold out of ADMA Biologics (ADMA) in Q4 2018, closing a stake of 107,000 shares — an estimated $664K sold.

Kepos Capital first reported a position in ADMA in Q2 2018 and held it in 2 quarters. The position peaked at $664K in Q3 2018. 52 funds tracked by Wall St. Rank hold ADMA as of Q4 2018.

Kepos Capital reported no remaining ADMA Biologics position as of Q4 2018 after selling out during the quarter.
Kepos Capital sold 107,000 ADMA Biologics shares in Q4 2018, an estimated $664K.
Kepos Capital first reported a position in ADMA Biologics in Q2 2018 and held it in 2 quarters.
Kepos Capital's ADMA Biologics position peaked at $664K in Q3 2018.
52 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.